Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 73
- Registration Number
- NCT02129257
- Locations
- 🇬🇷
2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital, Athens, Greece
🇬🇷2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio", Athens, Greece
🇬🇷Dept of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 56
- Registration Number
- NCT02118831
Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT02072408
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Gyunggi-do, Korea, Republic of
🇰🇷Konyang University Kim's Eye Hospital, Seoul, Korea, Republic of
Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 23
- Registration Number
- NCT02002377
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇨🇦Ivey Eye Institute, London, Ontario, Canada
🇨🇦St. Joseph's Centre for Ambulatory Services, Hamilton, Ontario, Canada
Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Rishi Singh
- Target Recruit Count
- 30
- Registration Number
- NCT01988246
- Locations
- 🇺🇸
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- The Emmes Company, LLC
- Target Recruit Count
- 362
- Registration Number
- NCT01969708
- Locations
- 🇺🇸
Emory University Eye Center, Atlanta, Georgia, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸Illinois Eye and Ear Infirmary UIC Dept. of Ophthalmology, Chicago, Illinois, United States
Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Registration Number
- NCT01965041
- Locations
- 🇺🇸
Ns/Lij Meeth, New York, New York, United States
Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Palmetto Retina Center, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT01961414
- Locations
- 🇺🇸
Eye Surgical Associates, Lincoln, Nebraska, United States
🇺🇸Retina Consultants Houston, Houston, Texas, United States
🇺🇸Southeast Retina, Augusta, Georgia, United States
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
- Conditions
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 712
- Registration Number
- NCT01958918
- Locations
- 🇨🇭
Novartis Investigative Site, Genève, Switzerland
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT01950741
- Locations
- 🇰🇷
Yeungnam University Medical Center, Nam-gu, Daegu, Korea, Republic of
🇰🇷Pusan National University Hospital, Seo-gu, Busan, Korea, Republic of
🇰🇷Haeundae Paik Hospital, Haeundae, Busan, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.